Reactive Oxygen Species Modulator 1 (Romo1) Predicts Poor Outcomes in Advanced Non-small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.
- Author:
Seung Hyeun LEE
1
;
Sue In CHOI
;
Ji Sung LEE
;
Chul Hwan KIM
;
Won Jai JUNG
;
Eun Joo LEE
;
Kyung Hoon MIN
;
Gyu Young HUR
;
Seung Heon LEE
;
Sung Yong LEE
;
Je Hyeong KIM
;
Sang Yeub LEE
;
Chol SHIN
;
Jae Jeong SHIM
;
Kyung Ho KANG
;
Kwang Ho IN
Author Information
- Publication Type:Original Article
- Keywords: Lung neoplasms; Biomarkers; Reactive oxygen species; Prognosis; Drug therapy; Platinum
- MeSH: Biomarkers; Carcinoma, Non-Small-Cell Lung*; Disease-Free Survival; Drug Therapy*; Humans; Immunohistochemistry; Lung Neoplasms; Multivariate Analysis; Platinum; Prognosis; Reactive Oxygen Species*; Smoke; Smoking
- From:Cancer Research and Treatment 2017;49(1):141-149
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Reactive oxygen species modulator 1 (Romo1) is a key mediator of intracellular reactive oxygen species production. However, examination of the clinical usefulness of Romo1 in cancers has been limited. We evaluated the association of Romo1 expression with clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. MATERIALS AND METHODS: Romo1 expression in tumor tissue was examined by immunohistochemistry and evaluated by histological score. Survival analyses were performed according to Romo1 expression and the association between Romo1 expression and clinical parameters was evaluated. RESULTS: A total of 88 tumor specimens were analyzed. Significantly shorter median progression-free survival (PFS) was observed in the high Romo1 group compared with the low Romo1 group (4.5 months vs. 9.8 months, p < 0.001), and the median overall survival (OS) of the high Romo1 group was also significantly shorter than that of the low Romo1 group (8.4 months vs. 15.5 months, p < 0.001). Results of multivariate analyses showed significant association of high Romo1 expression with both poor PFS (hazard ratio [HR], 2.75; 95% confidence interval [CI], 1.71 to 4.44) and poor OS (HR, 3.99; 95% CI, 2.36 to 6.74). Results of the subgroup analysis showed a similar association regardless of tumor histology. Romo1 expression showed no association with any clinical parameter including age, sex, smoking status, stage, differentiation, or tumor histology. CONCLUSION: Romo1 overexpression was associated with poor response to treatment and shorter survival in advanced NSCLC patients treated with platinum-based chemotherapy. Romo1 could be a potential adverse predictive marker in this setting.
